Introduction: Human papillomavirus (HPV) is a DNA virus which has tropism for epithelial cells, is the major etiological factor for development of cervical precancerous and cancerous lesions. Nearly 100 diff erent types of HPV have been characterized and thereare a large number of other types. HPV infection is one of the most common causes of sexually transmitted disease in both men and women worldwide. It is associated with a variety of clinical conditions that range from innocuous lesions to cancer. Genital HPV types are divided into high and low-risk types, according to the oncogenic potential. Molecular and epidemiologic studies have solidifi ed the association between high risk HPV types (especially HPV-16 and HPV-18) and cervical squamous cell carcinoma. HPV infection is often transient and self-limiting but infection may persists and progress to high grade lesions and cancer. In addition to persistent high-risk HPV infection, other viral factors such as high viral loads, HPV variants, infections with multiple high-risk HPV types and genetic predisposition contribute to the development of cervical cancer. Th e aim of the present study was to detect HPV DNA and identify high risk HPV genotype among women having cervical intraepithelial neoplasia and carcinoma and to evaluate potential effi cacy of prophylactic HPV vaccine. Methods: Cervical swab from histopathologically diagnosed CIN (n=51) and carcinoma (n=39) patients were taken and high risk HPV DNA was detected by HC II assay. Polymerase Chain Reaction was used to identify high risk HPV genotype. Result: HPV DNA was detected in 41 (45.56%) patients by HC II assay. HPV type 16 was detected in 27 (81.82%) followed by type 18 in 3 (9.09%) and type 45 in 2 (6.06%) cases of cervical carcinoma. Among precancerous cases, only type 16 was detected. Conclusion: Knowledge based on HPV prevalence and genotype could be used to predict the effi cacy of cost eff ective prophylactic vaccine, introduction of newer generation vaccine and management of cervical carcinoma.
INTRODUCTION
Human Papillomavirus infection is one of the most common sexually transmi ed diseases worldwide. Up to 70% of sexually active women globally may become infected with HPV during their lifetime. 1 Infection with oncogenic HPV types is the most signifi cant risk factor for developing cervical precancers and cancer. 2 HPV is responsible for development of cervical cancer & virtually every cervical cancer (99.7%) is HPV positive. 3 Some studies demonstrated that more than 90% of cervical cancers causes by HPV DNA, while decreasing order are-HPV 16 (64.8%), 18 (14.7%), 45 (6 9 Certain cervical intraepithelial neoplasias (CINs) with persistent HPV infection progress to invasive cervical cancer though a fraction of them regress during the course of time -60% in case of CIN I, 40% of CIN II and 33% in CIN III. 9 Thirty percent of CIN I persist, 10% progress to CIN III, and 1% progress to invasive cancers. Approximately 40% of all CINs persist and only about 1% of CIN I, 5% of CIN II and 15% of CIN III advance to invasive cancers. 10 In a study from Bangladesh, the prevalence of high risk HPV infection was detected in 60% of diff erent grades of CIN and 4.1% of control women. 11 Age specifi c incidence rates of cervical cancer in Bangladesh are highest compared to Southern Asia and the World (WHO/ICO Information Center on HPV Summary Report 2010). 12 Increased development of cervical cancer has been associated with other risk factors, which are responsible for interaction between host and virus which also increases the susceptibility of HPV infection. These factors are early age of sexual contact, multiple sexual partners, increased parity, poor sexual hygiene, prolonged use of oral contraceptives, smoking and altered immune status of the patients. 13, 14, 15 Other sexually transmi ed diseases such as Chlamydia trachomatis, Herpes simplex virus type II and Human immunodefi ciency virus as well as some poorly known dietary factors are likely intervening factors. 16 Identification of individual HPV types is essential to investigate the epidemiology and clinical characteristics of particular types. Detection of high-risk HPV types in genital specimens has been approved in several countries for women with a cytological diagnosis of atypical squamous cells of undetermined signifi cance (ASCUS) and also for primary cervical cancer screening in women aged 30 years and above as an adjunct to cytology. 17 In the management of women with ASCUS, HPV characterization helps improve the understanding of prevalence, individual risk stratification, persistence, reinfection, co-infection and development of eff ective vaccines. 18 Detection of typespecifi c HPV DNA in abnormal smears may be used as a more specifi c predictor of high-grade cervical intraepithelial neoplasia 19 and identifi cation of high-risk HPV genotypes may permit selection of patients who are at increased risk for disease. 20 Cervical cancer usually develops slowly from precursor lesions. Therefore, regular screening should be performed in order to provide a signifi cant impact on its morbidity and mortality. Screening every year or every three years play an important role in cervical cancer prevention programs. 21 The most powerful application of HPV genotyping is in primary screening. 22 Genotyping should be done to understand the prevalence of HPV of the respective country because there is regional variation in HPV genotypes among the female population. 23 Persistence of oncogenic HPV types is important risk factor and predictor of CIN's progression and cancer. 24 An eff ective genotyping test for HPV will contribute to identify woman who are at risk of developing cervical cancers, to monitor genotype specifi c HPV infection, towards the development of type specifi c vaccines and to determine the appropriate clinical management strategy. Presently, two vaccines are available: one is a quadrivalent vaccine named Gardasil (Merck & Co. USA) against type 6, 11, 16, 18 . Another bivalent vaccine prepared against type 16 and 18 named Cervarix (GlaxoSmithKline, UK) is being used in Bangladesh. Knowledge of prevalent genotypes in pre-cancer and cancer patients will contribute to the development of eff ective type specifi c vaccines.
First generation HPV16/18 vaccines have the potential to provide 75-80% protection against invasive cancer in India. HPV 45, 33, 35 and 58 which account for an additional 20% cases of cervical cancer should be considered for inclusion in second-generation HPV vaccines. 25 Theoretically, an HPV vaccine with 100% effi cacy in preventing HPV 16 and 18 infections could potentially reduce the cervical cancer burden by more than 60%, assuming 100% coverage. 26 The two methodologies most widely used for HPV DNA detection are PCR and Hybrid capture II system. 27 HPV DNA can be detected by hybridization techniques in approximately 89.0% of cervical cancers and approximately 33.8% of low-grade lesions. 28 It is designed to provide quantitative estimate loads, which may correlate with grade and natural history of cervical pathology. 29 It detects the DNA of the virus from cervical samples even years before this virus causes genital disease or cervical cancers that may spread to other organs of the reproductive system. The hybrid capture assay has proved to be a reliable, accurate and reproducible HPV test method for routine clinical practice. 30 Polymerase Chain Reaction is particularly useful for detection of HPV types with known DNA sequences from small amount of tissue specimens. 31 Among cervical carcinoma HPV DNA can be detected in 70% cases by type specifi c PCR. 32 This is a highly sensitive method 33 , easy to interpret and can characterize multiple virus types in case of multiple infection 34 or at least one virus type in cases of multiple infections.
In a study from Bangladesh, the most prevalent high-risk HPV types among women of high risk behavior were types 16 
MATERIALS AND METHODS

Study Population
After taking informed wri en consent, the patients were interviewed for detailed history which was recorded in a pre-designed data collection sheet. With all relevant history 150 patients, who were VIA positive and had clinically suspected sign symptoms for cervical precancerous and cancerous lesions were preliminarily selected and referred for colposcopy to BSMMU hospital. VIA test positive patients were advised to do colposcopy after 14 days of the test. After examining the cervix by Cuscos speculum, 2 cervical samples were collected by gynecologist from each patient using the Cervex-Brush (Digene, Germany) and processed by using a liquid-based cytology medium (Digene, Germany). Samples of primarily selected 150 cases were stored at -20 0 C at the Department of Virology, BSMMU. After that, colposcopy was performed. Out of the 150 preliminarily selected patients, 120 patients were diagnosed with cervical lesions by colposcopy and colposcopy guided cervical tissue was obtained for biopsy from these 120 patients. When all biopsy reports were available, 90 cervical pre-cancer and cancer cases were segregated. Then Hybrid Capture II assay and type specifi c PCR were carried out with the cervical swab samples of these 90 histological positive cases. The experimental protocol was approved by the Ethical Commi ee of the Bangabandhu Sheikh Mujib Medical University and wri en informed consent was obtained from all the subjects. 
RESULTS
Of the 90 patients enrolled in the study 41 
DISCUSSION
Accurate HPV genotyping is essential for adequate classifi cation of patients into low-risk or high-risk groups.
A number of studies have demonstrated that cervical cancer is associated with high-risk human papilloma virus (HPV) genotypes. 3 Presence of multiple genotypes may refl ect repeated exposure HPV infection. 5 Persistence of HPV infection has been identifi ed as an important risk factor for cervical carcinoma and should be included in clinical testing. 41 HPV infections can only be classifi ed as truly persistent if identical subtypes are detected in consecutive samples during follow-up studies. Persistent HPV infection is more common with the high-risk oncogenic HPV types and is an important determinant in the development of cervical cancers. 16 HPV viral load may also be a valuable predictor of disease. Thus, the present study was undertaken to detect HPV DNA and genotyping of some common high-risk HPV types among cervical precancer and cancer patients a ending the BSMMU hospital.
HPV prevalence was related to some risk factors in the present study. Before 18 years of age, 26 (49.06%) HPV positive patients had history of fi rst sexual exposure. In India, the association of infection of high-risk HPVs with the age of marriage below 18 years was found to increase the risk of cervical cancer by 22 fold. 42 Another study from India showed that the risk of HPV infection was higher in married women below 20 years of age (odds ratio, 1.80). 43 Women who began to have sexual experience before the age of 16 were found to have a two-fold higher risk of high-grade CIN and cervical cancer (OR=2.17, 95% CI=1.3-3.7) than women who had exposure for the fi rst time after the age of 16. 44 This increased risk may be due to the fact that younger age may have exposure to a persistent HPV infection for a longer time than women having exposure at later age. 45 The present study also demonstrated similar associations.
Significant association with parity and HPV infection (p value=0.001) was observed in the present study. A previous study observed that the risk of HPV infection was higher in women with parity ≥4 (odds ratio, 1.04). 43 In the large IARC study, women with seven or more fullterm pregnancies had a four-fold increase in the risk of developing squamous-cell carcinoma as compared with nulliparous women (odds ratio = 3.82, 95% CI: 2.66-5.48). Events related to the second and third trimesters of pregnancy or to delivery may be relevant with this factor. The concentrations of oestrogens and progesterone in blood are known to increase progressively during pregnancy to reach the highest levels in the last weeks of pregnancy. These hormonal changes are probably responsible for the alterations in the junction between the squamous and columnar epithelium (transformation zone) occurring during pregnancy, thus facilitating the direct exposure to HPV. 46 Long term oral contraceptive pill users are at risk of cervical cancers. 46 In this study, 23 (56.10%) HPV positive patients had history of taking oral contraceptive pills, while 6 (40%) HPV positive patients used barrier method for contraception. In terms of risk factor of hormonal contraception use, a study for International Agency for Research on Cancer, Multicentric Cervical Cancer Study Group showed that long-term use of oral contraceptives could be a cofactor as it increases risk of cervical carcinoma by up to four-fold in women who are positive for cervical HPV DNA. The odds ratio for use of oral contraceptives was 2.82 (95% CI=1.46-5.42) for 5-9 years, and 4.03 (95% CI=2.09-8.02) for use for 10 years or longer.
14 In addition, a study from Thailand also observed that the risk of cervical cancer increased with parity and use of oral contraceptives, but not with injectable progesteron. The study also found that factors that may predispose to persistent oncogenic HPV 16 or 18 infections may include estrogens or progestins in the presence of estrogens. 47 Hormonal-related mechanisms may infl uence the progression from pre-malignant to malignant cervical lesions by promoting integration of HPV-DNA into the host genome, which results in deregulation of E6 and E7 expression (IARC, 1995).
In the present study, 41 (45.56%) cases out of 90 cases were positive by HC II assay. Most importantly, out of 39 carcinoma cases, 35 (89.74%) cases were positive by this detection method. Other studies have indicated that HPV DNA positivity increases with severity of CIN and carcinoma (p trend=0.004). 40 Using this method, high-risk HPV DNA was detected in 96.7% of cervical cancer patients from Bangladesh. 48 DNA of the high risk HPV types was found in over 90% of cervical cancers and in their precursor lesions. 49, 50 Comparatively high viral load was detected in carcinoma cases than in other categories of histological diagnosis in the present study. Among 35 carcinoma cases, 11 (31.43%) cases had very high viral load. In HPV positive CIN's patients, 3 (50%) cases were from low viral load group indicating that probably when histological stage progresses, the viral load also increases. This was evident from the result of the present study where among 35 HC II positive carcinoma cases 3 (8.57%) had viral load <10 RLU index, 11 (31.43%) had viral load < 100 RLU index and 21 (60%) had viral load ≥ 100 RLU index. In this study, 60% of carcinoma showed a viral load of ≥ 100 RLU index. In a study, Cremoux 51 reported that 71% of cervical carcinoma had viral load ≥100 RLU index. Viral load of HR-HPV may vary between diff erent individuals of same histological types. The replication of HPV can only occur in the presence of episomal form of the genome, thus increasing the load rather than the integrated form. Co-infection with other types of HPV may decrease the viral load. 52 There is very few data available regarding the analysis of viral load in HC II assay. In a similar study, Toze i 53 stratifi ed the load into 4 groups, but in a retrospective study Xu 54 categorized them into three groups. Moderate to high viral loads of HR-HPV were found to be signifi cantly related to the histological grades of dysplasia (p=0.029). 54 Similar observations were also expressed by study conducted by Cremoux. In the present study, signifi cant relation was observed when histological fi ndings were analyzed with viral loads (Chi sq= 8.314, df= 3, p= 0.04). After comparative analysis of viral load and histological findings, it was observed that when histological severity increased the viral load also increased.
HPV genotype distribution among diff erent categories of cervical histology by TS-PCR amplifi cation of E6/E7 gene in this study detected 33 (36.67%) HPV positive cases. Importantly, out of 39 carcinoma cases, 30 (76.92%) cases were detected by this method. Increased prevalence of HR-HPV is related to the severity of cervical histopathology. So, the HR-HPV genotypes are associated with a risk of progression to cervical carcinoma. 55 Genotyping may be a useful tool for classifi cation of HPV positive women according to oncogenic potential and relative risk of progression to carcinoma, as well as for evaluating the effi ciency and epidemiological impact of vaccination programs. 56 In this study, some common highrisk HPV genotypes were identifi ed in CINs and cervical carcinoma. Among 33 genotyped HPV cases, 30 (90.9%) carcinoma cases were genotyped as type 16, 18 and 45. Types 16, 18, 45, 31, 33, 52, 58 , and 35 accounted for 95 percent of the squamous-cell carcinoma positive for HPV infection. These fi ndings have important implications for the prevention of cervical cancer. It implies that an eff ective vaccine against the fi ve most common HPV types may prevent about 90 percent of cervical cancers worldwide. However, regional variation in the distribution of certain HPV types should be taken into account in the creation of vaccines tailored for diff erent geographic regions. 21 In this study, HPV type 16 was detected in 24 (80%) cases of cervical carcinoma. By using specifi c primers for 18 and 45, 3 (10%) and 2 (6.67%) cases were detected respectively. HPV 16 was observed to be the most prevalent (80%) high risk types in case of carcinoma, followed by type 18 (10%) and type 45 (6.67%). A similar study detected HPV type 16 as the most commonly (89%) present type in cervical cancer patients. 57 In India, HPV 16 in cervical cancer is 70-90% while HPV type 18 varied from 3 to 20% (WHO, 2010), which corresponds with this study. The fi ve most frequent types from Brazil were HPV16 (77.6%), HPV 18 (12.3%), HPV 31 (8.8%), HPV 33 (7.1%) and HPV 35 (5.9%) in cervical carcinoma cases. 58 Most (75%) infections were caused by individual HPV types. 58 In case of squamous cell carcinoma, in most cases type 16 was identifi ed and in 2 cases of adenocarcinoma, one coinfection with type 18/45 and one type 16 was identifi ed. The distribution of HPV genotypes detected in cervical cancer varies depending on the histological type of the cancer. While HPV 16 is the most frequent genotype in SCC, HPV 18 is a predominant genotype in ADC. Some studies indicate that both HPV 16 and HPV 18 play a prominent role in the development of ADC of the cervix. 45 The most prevalent genotype detected in the present study was HPV 16 irrespective of cervical pathology. This fi nding correlates with a study from Thailand by Lurchachaiwong. 55 HPV18 is mainly a risk factor for development of adenocarcinoma. The carcinoma samples for the present study mostly comprised squamous cell carcinoma with only two samples diagnosed as adenocarcinoma. Unfortunately, due to small sample size, this fi nding could not be confi rmed in the present study. However, HPV16 and 18 are the most prevalent HPV types in cervical cancer worldwide, followed by types 45, 31, 33,52, 58 and 35. 24 The present study detected co-infection with more than one type (18/45) in only 1 (3.33%) case of carcinoma patients. The prevalence of multiple HPV infections varies in relation to the method used to detect HPV DNA. Various studies have reported diff erent prevalences, while 1.9% to 3.2% patients were reported to be infected with multiple HPVs in an individual visit. 59 In cervical carcinoma patients 8.1% were recorded to be infected with multiple types. Kleter 60 observed that multiple genotypes are less prevalent in carcinoma patients. However, some 61 observed that 35% HPV positive patients with advanced cytological disorder and >50% of HIV infected patients contained multiple HPV genotype. Single infection of HPV genotype have more signifi cant eff ect on increasing risk of high-grade cervical lesions than multiple infection of HPV genotypes. Moreover, the multiple HPV infections are less frequent in high-grade than low-grade cervical neoplasia. 54 There are various HPV types involved in cervical cancer depending on geographic distribution. In future, HPV testing will focus on primary screening and cervical cancer prevention. HPV genotype distribution will provide basic knowledge for HPV-based cervical cancer screening, cost-eff ective prophylactic HPV vaccine and assessment of vaccination against specific HPV infection in each geographic area. 56 A second generation HPV vaccine should focus on HPV 31, 33, 35, 45, 52 and 58 for prevention of HPV infection in all regions of the world. In routine set-up or high-throughput, HPV typing is feasible. 60 Since cervical cancer is the only cancer that is almost completely preventable through regular screening, further implementation of eff ectively organized screening programs and improvement of existing screening strategies and technologies will inevitably decrease the burden of this disease. 61 At present, a HPV genotyping assay has been adopted in developed regions as a main method for screening cervical lesions. A HPV vaccine is currently the fi rst choice for the prevention of HPV infection and consequent reduction of the incidence of cervical cancers. 62 Reliable identifi cation of HPV genotypes may be relevant for patient management. In addition to study the eff ects of antiviral treatment or type specifi c vaccination, accurate HPV genotyping methods are essential. The knowledge of HPV genotyping of cervical cancer within a country or region is important for both primary screening and vaccination policy.
CONCLUTION AND RECOMMENDATIONS
Very high viral load was observed in cancerous patient than precancerous patients. Type 16 (81.82%) was identifi ed as the most prevalent HPV genotype, followed by type 18 (9.09%) and type 45 (6.06%). Type 31 and 33 could not be detected due to small sample size or due to the lesser prevalence. In all histological staging, type 16 was the most prevalent type. In the present study mixed infection with more than one type were also observed.
The data obtained from the present study provided some important background information that may be the basis of further elaborative and systemic studies. Higher education, be er socioeconomic condition, awareness, detection and genotyping of HPV DNA can reduce the possibilities of progression of cervical carcinoma. Although various HPV types are involved in cervical cancer depending on geographical distribution, to achieve more reliable data and to detect these genotypes, testing should include all high risk HPV genotypes. Distribution of HPV genotype will provide basic knowledge for HPV based cervical cancer screening, cost eff ective HPV vaccines, follow up of effi cacy of recently available vaccine, and introduction of newer and more eff ective vaccines.
LIMITATIONS OF STUDY
• Since all high risk HPV types were not included in this study, less numbers of genotypes were identifi ed.
• It was not possible to observe the genotypes with progression of lesions due to limited study period.
• The exact prevalence of HPV types in Bangladesh could not be identifi ed as the present study was conducted on hospital based specimens due to time and budget constrains.
